一、教育与工作经历

     教育经历

w  博士 肿瘤学, 2016.9- 2019.6

南京医科大学

w  硕士 肿瘤学, 2006.9-2009.6

中南大学湘雅医学院

w  本科 临床医学, 2001.9-2006.6

           中南大学湘雅医学院

    工作经历

w  副主任医师 放疗科 2019.12至今

南京医科大学附属肿瘤医院

w  主治医师     放疗科 2014.12 – 2019.11

南京医科大学附属肿瘤医院

w  住院医师     放疗科 2009.09 – 2014.11

南京医科大学附属肿瘤医院

二、科研与学术经历

访问学者：2019年9月-2020年9月 美国安德森肿瘤中心

三、主持或参与科研项目（课题）情况

①    主持：外泌体中microRNA作为鼻咽癌血清新型生物标志物的研究.

江苏省卫生健康委员会青年课题 (No. Q201601), 2017-2019

②    主持：鼻咽癌患者血清中DNA甲基化的研究

江苏省肿瘤医院青年创新研究项目(No. ZQ201304), 2014-2016

③    主要参与者：长链非编码RNA RP11-1100L3.8对非小细胞肺癌厄洛替尼耐药的机制研究. 

国自然青年基金 (No. 81502678), 2016-2019

④ 参与者：环状RNA circ-0046263调控鼻咽癌侵袭转移的机制研究

国自然青年基金 (No. 81702685), 2017-2020

四、代表性研究成果和学术奖励情况

     发表论著：

     1 Wu L, Wang J, Zhu D, Zhang S, Zhou X, Zhu J, He X: Circulating Epstein-Barr virus microRNA profile reveals novel biomarker for nasopharyngeal carcinoma             diagnosis. Cancer Biomark. 2020, 27(3):365-375.

2 Huo Zhang, Xuan Zou, Lirong Wu (并列第一作者), Shiyu Zhang, Tongshan Wang, Ping Liu, Wei Zhu, Jun Zhu. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection. Cancer Medicine 2020, 9(3): 1230-1241.

3  Lirong Wu，Xiuming Zhang, Xiaodong Xie, Yue Lu, Jianfeng Wu, Xia He*. Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with 10-year follow-up. Oral Oncol. 2019; 98: 141-146.

4  Lirong Wu，Kexiao Zheng, Cheng Yan, Xuan Pan, Yatian Liu, Juying Liu, Feijiang Wang, Wenjie Guo, Xia He*, Jiong Li*, Ye Shen*. Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma. BMC Cancer. 2019; 19:843.

5  Zong D, Jiang N, Xu JH, Wang DJ, Zhu HF, Wu LR, Chen C, Yin L, He X. ZNF488 is an independent prognostic indicator in nasopharyngeal carcinoma and promotes cell adhesion and proliferation via collagen IV/FAK/AKT/Cyclin D1 pathway. Cancer Manag Res. 2019, 28(11):5871-5882.

6  Wu LR，Zhu HF, Xu JH, Jiang Xs, Yin L, Jiang N, Zong Dan, Wang FJ, Huang SF, Bian XH, Wu JF, Song D, Guo WJ, Liu JY, He X. Effectiveness of Cetuximab in Combination with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A 1:2 Propensity Score- matched Analysis. Journal of Cancer. 2018; 9(9): 1642-1651.

7  Wu LR，Liu YT，Jiang N，Fan YX, Wen J, Huang SF, Guo WJ, Bian XH, Wang FJ, Li F, Song D, Wu JF, Jiang XS, Liu JY, He X. Ten-year Survival  Outcomes for Patients with Nasopharyngeal Carcinoma Receiving Intensity Modulated Radiotherapy: An Analysis of 614 Patients from a Single Center. Oral Oncol. 2017; 69, 26–32.

8  Wu LR，Jiang XS，Song X，Yu HL, Fan YX, Wang FJ, Huang SF, Guo WJ, He X, Liu JY. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis. Oncotarget. 2017; 8, 79953-79963.

9  Wu LR,  Yu H, Jiang N, Jiang XS, Zong D, Wen J, Huang L, Xie P, Chen W, Wang TT, Gu DY, Yan PW, Yin L, He X. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study. Oncotarget. 2017; 8, 76807-76815.

10    Liu JY, Chen W, Chen ZZ, Wen J, Yu HL, Wang F, Wu LR (共同通讯作者), He X. The effects of microRNA-98 inhibits cell proliferation and invasion by targeting STAT3 in nasopharyngeal carcinoma. Biomed Pharmacother. 2017; 93, 869-878.

11    Huang ZB, Zhu DX, Wu LR (并列第一作者),  He MF, Zhou X, Zhang L, Zhang H, Wang WW, Zhu J, Cheng WF, Chen Y, Fan Y, Qi LW, Yin Y, Zhu W, Shu YQ, Liu P. Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer. Cancer Epidemiol Biomarkers Prev. 2017; 26, 188-196. 

12    Jiang N, Jiang XS, Chen ZZ, Song X, Wu LR, Zong D, Song D, Yin L, Wang DJ, Chen C, Bian XH, He X. MiR-203a-3p suppresses cell proliferation and metastasis through inhibiting LASP1 in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2017; 36, 138.

国际会议摘要（壁报展示）

1   Lirong Wu, Xiangzhi Zhu, Zhongxing Liao, Ting Xu, Percy Lee, Nils Petter Rudqvist, James Welsh, Xuefeng Xia, Rong Yin, Jun Zhu, Xia He. TCR profiling to assess the efficacy/prognosis of Stereotactic Body Radiation Therapy in Stage I Non-Small-Cell Lung Cancer. American Society for Radiation Oncology (ASTRO) 2020 Congress. Miami, United States.  (Publication Number: 2243). 

2  Li-Rong Wu, Zhang, Xiuming; Xie, Xiao-Dong; Lu, Yue; Wu, Jian-Feng; He Xia. Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with 10-year follow-up. European Society for Medical Oncology (ESMO) Asia Congress 2019. Singapore. 22-24 November, 2019 (Publication Number: 294P).

3 Li-Rong Wu, Xia He, Ye Shen. Genome-Wide Study of Salivary microRNAs As Potential Noninvasive Biomarkers for Detection of Nasopharyngeal Carcinoma. American Society for Radiation Oncology (ASTRO) 2019 Congress. Chicago, United States. 15-18 September, 2018 (Publication Number: 3555). 

4    Li-Rong Wu, Huan-feng Zhu, Jianhua Xu, Xiu-hua Bian, Jian-feng Wu, Dan Song, Xue-song Jiang, Feng Li, Fei-jiang Wang, Sheng-fu Huang, Wen-jie Guo, Xia He. Effectiveness and toxicities of cetuximab in combination with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. European Societyfor Medical Oncology (ESMO) 2017 Congress. Annals of Oncology. Madrid, Spain 8-12 September, 2017 (Publication Number: 1072P).

      获得奖项：

       1、2019年江苏省新技术引进奖一等奖 1项 排名第一

       2、2019年获得欧洲肿瘤年会 ESMO Merit Award奖 1项  排名第一

      获得专利：

      实用新型专利一项   一种鼻咽癌腔内放疗辅助用施源器（专利号：ZL 2019 2 0344851.6） 排名第一

      编译书籍：

      参与编写人卫版教材《肿瘤放射治疗学》，参与编译《血液系统恶性肿瘤放射治疗》、《亨迪放射治疗物理学》(第4版)。